Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2011, Article ID 741974, 15 pages
http://dx.doi.org/10.4061/2011/741974
Review Article

Melatonin and Its Agonist Ramelteon in Alzheimer's Disease: Possible Therapeutic Value

1Sri Sathya Sai Medical Educational and Research Foundation, Prasanthi Nilayam, 40- Kovai Thirunagar, Coimbatore 641014, India
2Department of Physiology, Faculty of Medicine, Karpagam University, Eachanari, Coimbatore 641021, India
3Department of Anatomy, Yong Loo Lin School of Medicine, Block MD10, Medical Drive, National University of Singapore, Singapore 117597
4Somnogen Inc., College Street, Toronto, ON, Canada M6H 1C5
5Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada M5T 1RS
6Departmento de Docencia e Investigación, Facultad de Ciencias Médicas, Pontificia Universidad Católica Argentina, Avenida Alicia Moreau de Justo 1500, 4° piso, 1107 Buenos Aires, Argentina

Received 21 September 2010; Revised 8 October 2010; Accepted 27 October 2010

Academic Editor: Anthony R. White

Copyright © 2011 Venkatramanujam Srinivasan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. Palop and L. Mucke, “Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks,” Nature Neuroscience, vol. 13, no. 7, pp. 812–818, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Mancuso, D. Orsucci, A. LoGerfo, V. Calsolaro, and G. Siciliano, “Clinical features and pathogenesis of Alzheimer's disease: involvement of mitochondria and mitochondrial DNA,” Advances in Experimental Medicine and Biology, vol. 685, pp. 34–44, 2010. View at Google Scholar
  3. C. Behl, J. B. Davis, R. Lesley, and D. Schubert, “Hydrogen peroxide mediates amyloid β protein toxicity,” Cell, vol. 77, no. 6, pp. 817–827, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Hensley, J. M. Carney, M. P. Mattson et al., “A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 3270–3274, 1994. View at Google Scholar
  5. M. A. Pappolla, Y. J. Chyan, B. Poeggeler et al., “An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease,” Journal of Neural Transmission, vol. 107, no. 2, pp. 203–231, 2000. View at Google Scholar · View at Scopus
  6. R. H. Swerdlow, J. M. Burns, and S. M. Khan, “The Alzheimer's disease mitochondrial cascade hypothesis,” Journal of Alzheimer's Disease, vol. 20, supplement 2, pp. S265–S279, 2010. View at Publisher · View at Google Scholar
  7. W. E. Müller, A. Eckert, C. Kurz, G. P. Eckert, and K. Leuner, “Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease-therapeutic aspects,” Molecular Neurobiology, vol. 41, no. 2-3, pp. 159–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Viña and A. Lloret, “Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-β peptide,” Journal of Alzheimer's Disease, vol. 20, supplement 2, pp. S527–S533, 2010. View at Publisher · View at Google Scholar
  9. B. F. Oliveira, J. A. Nogueira-Machado, and M. M. Chaves, “The role of oxidative stress in the aging process,” Scientific World Journal, vol. 10, pp. 1121–1128, 2010. View at Publisher · View at Google Scholar
  10. A. R. Hipkiss, “Mitochondrial dysfunction, proteotoxicity, and aging: causes or effects, and the possible impact of NAD+-controlled protein glycation,” Advances in Clinical Chemistry, vol. 50, pp. 123–150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Calabrese, C. Cornelius, C. Mancuso, R. Lentile, A. M. Stella, and D. A. Butterfield, “Redox homeostasis and cellular stress response in aging and neurodegeneration,” Methods in Molecular Biology, vol. 610, pp. 285–308, 2010. View at Google Scholar · View at Scopus
  12. G. Candore, M. Bulati, C. Caruso et al., “Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in alzheimer disease: therapeutic implications,” Rejuvenation Research, vol. 13, no. 2-3, pp. 301–313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Mandrekar-Colucci and G. E. Landreth, “Microglia and inflammation in Alzheimer's disease,” CNS and Neurological Disorders—Drug Targets, vol. 9, no. 2, pp. 156–167, 2010. View at Google Scholar · View at Scopus
  14. M. Fiala, “Re-balancing of inflammation and Aβ immunity as a therapeutic for Alzheimer's disease-view from the bedside,” CNS and Neurological Disorders—Drug Targets, vol. 9, no. 2, pp. 192–196, 2010. View at Google Scholar · View at Scopus
  15. T. Nakagawa, H. Zhu, N. Morishima et al., “Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β,” Nature, vol. 403, no. 6765, pp. 98–103, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Fotuhi, V. Hachinski, and P. J. Whitehouse, “Changing perspectives regarding late-life dementia,” Nature Reviews Neurology, vol. 5, no. 12, pp. 649–658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Beaulieu-Bonneau and C. Hudon, “Sleep disturbances in older adults with mild cognitive impairment,” International Psychogeriatrics, vol. 21, no. 4, pp. 654–666, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Cochen, C. Arbus, M. E. Soto et al., “Sleep disorders and their impacts on healthy, dependent, and frail older adults,” Journal of Nutrition, Health and Aging, vol. 13, no. 4, pp. 322–329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. F. Vecchierini, “Sleep disturbances in Alzheimer's disease and other dementias,” Psychologie et NeuroPsychiatrie du Vieillissement, vol. 8, no. 1, pp. 15–23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. D. J. Skene, B. Vivient-Roels, D. L. Sparks et al., “Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease,” Brain Research, vol. 528, no. 1, pp. 170–174, 1990. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Y. Liu, J. N. Zhou, J. van Heerikhuize, M. A. Hofman, and D. F. Swaab, “Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-ε4/4 genotype,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 1, pp. 323–327, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Mishima, T. Tozawa, K. Satoh, Y. Matsumoto, Y. Hishikawa, and M. Okawa, “Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking,” Biological Psychiatry, vol. 45, no. 4, pp. 417–421, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Srinivasan, S. R. Pandi-Perumal, D. P. Cardinali, B. Poeggeler, and R. Hardeland, “Melatonin in Alzheimer's disease and other neurodegenerative disorders,” Behavioral and Brain Functions, vol. 2, article 15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Kaur, V. Sivakumar, J. Lu, and E. A. Ling, “Increased vascular permeability and nitric oxide production in response to hypoxia in the pineal gland,” Journal of Pineal Research, vol. 42, no. 4, pp. 338–349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Sakotnik, P. M. Liebmann, K. Stoschitzky et al., “Decreased melatonin synthesis in patients with coronary artery disease,” European Heart Journal, vol. 20, no. 18, pp. 1314–1317, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Girotti, M. Lago, O. Ianovsky et al., “Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease,” Journal of Pineal Research, vol. 29, no. 3, pp. 138–142, 2000. View at Google Scholar · View at Scopus
  27. L. Girotti, M. Lago, O. Ianovsky et al., “Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure,” Endocrine, vol. 22, no. 3, pp. 245–248, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Peers, H. A. Pearson, and J. P. Boyle, “Hypoxia and Alzheimer's disease,” Essays in Biochemistry, vol. 43, pp. 153–164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Guglielmotto, M. Aragno, R. Autelli et al., “The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1α,” Journal of Neurochemistry, vol. 108, no. 4, pp. 1045–1056, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. X. Zhang, K. Zhou, R. Wang et al., “Hypoxia-inducible factor 1α (HIF-1α)-mediated hypoxia increases BACE1 expression and β-amyloid generation,” Journal of Biological Chemistry, vol. 282, no. 15, pp. 10873–10880, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Zhang and W. Le, “Pathological role of hypoxia in Alzheimer's disease,” Experimental Neurology, vol. 223, no. 2, pp. 299–303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. K.-M. Ng, C.-F. Lau, and M.-L. Fung, “Melatonin reduces hippocampal β-amyloid generation in rats exposed to chronic intermittent hypoxia,” Brain Research, vol. 1354, no. C, pp. 163–171, 2010. View at Publisher · View at Google Scholar
  33. M. Aldhous, C. Franey, J. Wright, and J. Arendt, “Plasma concentrations of melatonin in man following oral absorption of different preparations,” British Journal of Clinical Pharmacology, vol. 19, no. 4, pp. 517–521, 1985. View at Google Scholar · View at Scopus
  34. S. A. Ferguson, S. M. W. Rajaratnam, and D. Dawson, “Melatonin agonists and insomnia,” Expert Review of Neurotherapeutics, vol. 10, no. 2, pp. 305–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. R. Pandi-Perumal, V. Srinivasan, D. W. Spence et al., “Ramelteon: a review of its therapeutic potential in sleep disorders,” Advances in Therapy, vol. 26, no. 6, pp. 613–626, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. G. M. Brown, D. P. Cardinali, and S. R. Pandi-Perumal, “Melatonin and mental illness,” in Sleep and Mental Illness, S. R. Pandi-Perumal and M. Kramer, Eds., Cambridge University Press, Cambridge, UK, 2010. View at Google Scholar
  37. D. C. Klein, “Arylalkylamine N-acetyltransferase: "the timezyme",” Journal of Biological Chemistry, vol. 282, no. 7, pp. 4233–4237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. D. C. Klein, M. J. Bailey, D. A. Carter et al., “Pineal function: impact of microarray analysis,” Molecular and Cellular Endocrinology, vol. 314, no. 2, pp. 170–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Tricoire, A. Locatelli, P. Chemineau, and B. Malpaux, “Melatonin enters the cerebrospinal fluid through the pineal recess,” Endocrinology, vol. 143, no. 1, pp. 84–90, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Leston, C. Harthé, J. Brun et al., “Melatonin is released in the third ventricle in humans. A study in movement disorders,” Neuroscience Letters, vol. 469, no. 3, pp. 294–297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. R. J. Reiter and D. X. Tan, “Role of CSF in the transport of melatonin,” Journal of Pineal Research, vol. 33, no. 1, article 61, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. S. F. Pang and G. M. Brown, “Regional concentrations of melatonin in the rat brain in the light and dark period,” Life Sciences, vol. 33, no. 12, pp. 1199–1204, 1983. View at Google Scholar · View at Scopus
  43. M. D. Catalá, W. B. Quay, and P. S. Timiras, “Lower tryptophan:phenylalanine ratios in culture media increase medium: pineal melatonin ratios in early dark but not late light phase,” Journal of Pineal Research, vol. 4, no. 3, pp. 267–275, 1987. View at Google Scholar · View at Scopus
  44. D. P. Cardinali, R. E. Rosenstein, D. A. Golombek et al., “Melatonin binding sites in brain: single or multiple?” Advances in Pineal Research, vol. 5, pp. 159–165, 1991. View at Google Scholar
  45. G. Facciolá, M. Hidestrand, C. von Bahr, and G. Tybring, “Cytochrome P isoforms involved in melatonin metabolism in human liver microsomes,” European Journal of Clinical Pharmacology, vol. 56, no. 12, pp. 881–888, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Hirata, O. Hayaishi, T. Tokuyama, and S. Senoh, “In vitro and in vitro formation of two new metabolites of melatonin,” Journal of Biological Chemistry, vol. 249, no. 4, pp. 1311–1313, 1974. View at Google Scholar · View at Scopus
  47. R. Hardeland, D. X. Tan, and R. J. Reiter, “Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines,” Journal of Pineal Research, vol. 47, no. 2, pp. 109–126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. D. X. Tan, L. C. Manchester, R. J. Reiter et al., “A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation,” Biochemical and Biophysical Research Communications, vol. 253, no. 3, pp. 614–620, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. R. J. Reiter, “The melatonin rhythm: both a clock and a calendar,” Experientia, vol. 49, no. 8, pp. 654–664, 1993. View at Google Scholar · View at Scopus
  50. D. Dawson and S. M. Armstrong, “Chronobiotics—drugs that shift rhythms,” Pharmacology and Therapeutics, vol. 69, no. 1, pp. 15–36, 1996. View at Publisher · View at Google Scholar · View at Scopus
  51. R. J. Wurtman and I. Zhdanova, “Improvement of sleep quality by melatonin,” Lancet, vol. 346, no. 8988, p. 1491, 1995. View at Google Scholar · View at Scopus
  52. J. M. Monti, F. Alvariño, D. Cardinali, I. Savio, and A. Pintos, “Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia,” Archives of Gerontology and Geriatrics, vol. 28, no. 2, pp. 85–98, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Carrillo-Vico, R. J. Reiter, P. J. Lardone et al., “The modulatory role of melatonin on immune responsiveness,” Current Opinion in Investigational Drugs, vol. 7, no. 5, pp. 423–431, 2006. View at Google Scholar · View at Scopus
  54. V. Srinivasan, G. J. M. Maestroni, D. P. Cardinali, A. I. Esquifino, S. R. Pandi Perumal, and S. C. Miller, “Melatonin, immune function and aging,” Immunity and Ageing, vol. 2, article 17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. R. J. Reiter, J. J. Garcia, and J. Pie, “Oxidative toxicity in models of neurodegeneration: responses to melatonin,” Restorative Neurology and Neuroscience, vol. 12, no. 2-3, pp. 135–142, 1998. View at Google Scholar · View at Scopus
  56. R. J. Reiter, D. X. Tan, and L. Fuentes-Broto, “Melatonin: a multitasking molecule,” Progress in Brain Research, vol. 181, pp. 127–151, 2010. View at Google Scholar
  57. R. J. Reiter, “The pineal and its hormones in the control of reproduction in mammals,” Endocrine Reviews, vol. 1, no. 2, pp. 109–131, 1980. View at Google Scholar · View at Scopus
  58. R. J. Reiter, D. X. Tan, L. C. Manchester, S. D. Paredes, J. C. Mayo, and R. M. Sainz, “Melatonin and reproduction revisited,” Biology of Reproduction, vol. 81, no. 3, pp. 445–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. V. Srinivasan, W. D. Spence, S. R. Pandi-Perumal, R. Zakharia, K. P. Bhatnagar, and A. Brzezinski, “Melatonin and human reproduction: shedding light on the darkness hormone,” Gynecological Endocrinology, vol. 25, no. 12, pp. 779–785, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. D. E. Blask, L. A. Sauer, and R. T. Dauchy, “Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy,” Current Topics in Medicinal Chemistry, vol. 2, no. 2, pp. 113–132, 2002. View at Google Scholar · View at Scopus
  61. B. Jung-Hynes, R. J. Reiter, and N. Ahmad, “Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer,” Journal of Pineal Research, vol. 48, no. 1, pp. 9–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. A. J. Lewy, “Circadian misalignment in mood disturbances,” Current Psychiatry Reports, vol. 11, no. 6, pp. 459–465, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. S. R. Pandi-Perumal, I. Trakht, G. M. Brown, and D. P. Cardinali, “Melatonin, circadian dysregulation, and sleep in mental disorders,” Primary Psychiatry, vol. 15, no. 5, pp. 77–82, 2008. View at Google Scholar · View at Scopus
  64. S. M. Reppert, D. R. Weaver, and T. Ebisawa, “Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses,” Neuron, vol. 13, no. 5, pp. 1177–1185, 1994. View at Publisher · View at Google Scholar · View at Scopus
  65. S. M. Reppert, C. Godson, C. D. Mahle, D. R. Weaver, S. A. Slaugenhaupt, and J. F. Gusella, “Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel(1b) melatonin receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 19, pp. 8734–8738, 1995. View at Publisher · View at Google Scholar · View at Scopus
  66. M. L. Dubocovich, P. Delagrange, D. N. Krause, D. Sugden, D. P. Cardinali, and J. Olcese, “International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors,” Pharmacological Reviews, vol. 62, no. 3, pp. 343–380, 2010. View at Publisher · View at Google Scholar
  67. C. Carlberg and I. Wiesenberg, “The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship,” Journal of Pineal Research, vol. 18, no. 4, pp. 171–178, 1995. View at Google Scholar · View at Scopus
  68. A. M. Jetten, S. Kurebayashi, and E. Ueda, “The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes,” Progress in Nucleic Acid Research and Molecular Biology, vol. 69, pp. 205–247, 2001. View at Google Scholar · View at Scopus
  69. G. Benítez-King, “Melatonin as a cytoskeletal modulator: implications for cell physiology and disease,” Journal of Pineal Research, vol. 40, no. 1, pp. 1–9, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. D. P. Cardinali and F. Freire, “Melatonin effects on brain. Interaction with microtubule protein, inhibition of fast axoplasmic flow and induction of crystaloid and tubular formations in the hypothalamus,” Molecular and Cellular Endocrinology, vol. 2, no. 5, pp. 317–330, 1975. View at Google Scholar · View at Scopus
  71. Y. Urata, S. Honma, S. Goto et al., “Melatonin induces γ-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells,” Free Radical Biology and Medicine, vol. 27, no. 7-8, pp. 838–847, 1999. View at Publisher · View at Google Scholar · View at Scopus
  72. V. Srinivasan, S. R. Pandi-Perumal, G. J. M. Maestroni, A. I. Esquifino, R. Hardeland, and D. P. Cardinali, “Role of melatonin in neurodegenerative diseases,” Neurotoxicity Research, vol. 7, no. 4, pp. 293–318, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Kaur and E. A. Ling, “Antioxidants and neuroprotection in the adult and developing central nervous system,” Current Medicinal Chemistry, vol. 15, no. 29, pp. 3068–3080, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. A. Pappolla, M. Sos, R. A. Omar et al., “Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide,” Journal of Neuroscience, vol. 17, no. 5, pp. 1683–1690, 1997. View at Google Scholar · View at Scopus
  75. M. A. Pappolla, Y. J. Chyan, B. Poeggeler et al., “Alzheimer β protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin,” Journal of Pineal Research, vol. 27, no. 4, pp. 226–229, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. M. A. Pappolla, M. J. Simovich, T. Bryant-Thomas et al., “The neuroprotective activities of melatonin against the Alzheimer β-protein are not mediated by melatonin membrane receptors,” Journal of Pineal Research, vol. 32, no. 3, pp. 135–142, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Pérez, F. Hernández, A. Gómez-Ramos, M. Smith, G. Perry, and J. Avila, “Formation of aberrant phosphotau fibrillar polymers in neural cultured cells,” European Journal of Biochemistry, vol. 269, no. 5, pp. 1484–1489, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. G. Benitez-King, I. Túnez, A. Bellon, G. G. Ortíz, and F. Antón-Tay, “Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in N1E-115 cells,” Experimental Neurology, vol. 182, no. 1, pp. 151–159, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. K. K. Ting, B. Brew, and G. Guillemin, “The involvement of astrocytes and kynurenine pathway in Alzheimer's disease,” Neurotoxicity Research, vol. 12, no. 4, pp. 247–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. F. M. Harris, I. Tesseur, W. J. Brecht et al., “Astroglial regulation of apolipoprotein E expression in neuronal cells: implications for Alzheimer's disease,” Journal of Biological Chemistry, vol. 279, no. 5, pp. 3862–3868, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. F. Malchiodi-Albedi, M. R. Domenici, S. Paradisi, A. Bernardo, M. A. Ajmone-Cat, and L. Minghetti, “Astrocytes contribute to neuronal impairment in βA toxicity increasing apoptosis in rat hippocampal neurons,” GLIA, vol. 34, no. 1, pp. 68–72, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. Z. Feng and J. T. Zhang, “Protective effect of melatonin on β-amyloid-induced apoptosis in rat astroglioma c6 cells and its mechanism,” Free Radical Biology and Medicine, vol. 37, no. 11, pp. 1790–1801, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. B. Poeggeler, L. Miravalle, M. G. Zagorski et al., “Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the alzheimer amyloid Aβ peptidet,” Biochemistry, vol. 40, no. 49, pp. 14995–15001, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. E. Matsubara, T. Bryant-Thomas, J. P. Quinto et al., “Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease,” Journal of Neurochemistry, vol. 85, no. 5, pp. 1101–1108, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. X. Cheng and R. B. van Breemen, “Mass spectrometry-based screening for inhibitors of β-amyloid protein aggregation,” Analytical Chemistry, vol. 77, no. 21, pp. 7012–7015, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. B. Poeggeler, M. A. Pappolla, R. Hardeland et al., “Indole-3-propionate: a potent hydroxyl radical scavenger in rat brain,” Brain Research, vol. 815, no. 2, pp. 382–388, 1999. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. J. Chyan, B. Poeggeler, R. A. Omar et al., “Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid,” Journal of Biological Chemistry, vol. 274, no. 31, pp. 21937–21942, 1999. View at Publisher · View at Google Scholar · View at Scopus
  88. J. R. Harris and N. G. Milton, “Cholesterol in Alzheimer's disease and other amyloidogenic disorders,” Sub-Cellular Biochemistry, vol. 51, pp. 47–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. Z. Feng, Y. Chang, Y. Cheng et al., “Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease,” Journal of Pineal Research, vol. 37, no. 2, pp. 129–136, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. J. M. Olcese, C. Cao, T. Mori et al., “Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease,” Journal of Pineal Research, vol. 47, no. 1, pp. 82–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. X. C. Li, ZE. F. Wang, J. X. Zhang, Q. Wang, and J. Z. Wang, “Effect of melatonin on calyculin A-induced tau hyperphosphorylation,” European Journal of Pharmacology, vol. 510, no. 1-2, pp. 25–30, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. X. Yang, Y. Yang, Z. Fu Jr et al., “Melatonin ameliorates alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A,” Journal of Psychopharmacology. In press.
  93. Y. Q. Deng, G. G. Xu, P. Duan, Q. Zhang, and J. Z. Wang, “Effects of melatonin on wortmannin-induced tau hyperphosphorylation,” Acta Pharmacologica Sinica, vol. 26, no. 5, pp. 519–526, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. S. J. Liu and J. Z. Wang, “Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin,” Acta Pharmacologica Sinica, vol. 23, no. 2, pp. 183–187, 2002. View at Google Scholar · View at Scopus
  95. X. C. Wang, J. Zhang, X. Yu et al., “Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat,” Acta Physiologica Sinica, vol. 57, no. 1, pp. 7–12, 2005. View at Google Scholar
  96. G. Olivieri, U. Otten, F. Meier et al., “β-amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin,” Neuroscience, vol. 120, no. 3, pp. 659–665, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. J. B. Hoppe, R. L. Frozza, A. P. Horn et al., “Amyloid-β neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3β, tau and neuroinflammation,” Journal of Pineal Research, vol. 48, no. 3, pp. 230–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. A. M. Furio, R. A. Cutrera, V. C. Thea et al., “Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei,” Cellular and Molecular Neurobiology, vol. 22, no. 5-6, pp. 699–709, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. D. A. Weldemichael and G. T. Grossberg, “Circadian rhythm disturbances in patients with Alzheimer's disease: a review,” International Journal of Alzheimer's Disease, vol. 2010, Article ID 716453, 2010. View at Publisher · View at Google Scholar
  100. D. G. Harper, E. G. Stopa, A. C. McKee et al., “Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration,” Archives of General Psychiatry, vol. 58, no. 4, pp. 353–360, 2001. View at Google Scholar · View at Scopus
  101. E. J. W. van Someren, “Circadian and sleep disturbances in the elderly,” Experimental Gerontology, vol. 35, no. 9-10, pp. 1229–1237, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. E. J. W. van Someren, “More than a marker: interaction between the circadian regulation of temperature and sleep, age-related changes, and treatment possibilities,” Chronobiology International, vol. 17, no. 3, pp. 313–354, 2000. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Klaffke and J. Staedt, “Sundowing and circadian rhythm disorders in dementia,” Acta Neurologica Belgica, vol. 106, no. 4, pp. 168–175, 2006. View at Google Scholar · View at Scopus
  104. S. R. Pandi-Perumal, L. K. Seils, L. Kayumov et al., “Senescence, sleep, and circadian rhythms,” Ageing Research Reviews, vol. 1, no. 3, pp. 559–604, 2002. View at Publisher · View at Google Scholar · View at Scopus
  105. R. F. Riemersma-van der Lek, D. F. Swaab, J. Twisk, E. M. Hol, W. J. G. Hoogendijk, and E. J. W. van Someren, “Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial,” Journal of the American Medical Association, vol. 299, no. 22, pp. 2642–2655, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. Ohashi, N. Okamoto, K. Uchida, M. Iyo, N. Mori, and Y. Morita, “Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type,” Biological Psychiatry, vol. 45, no. 12, pp. 1646–1652, 1999. View at Publisher · View at Google Scholar · View at Scopus
  107. J. N. Zhou, R. Y. Liu, W. Kamphorst, M. A. Hofman, and D. F. Swaab, “Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels,” Journal of Pineal Research, vol. 35, no. 2, pp. 125–130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. D. J. Skene and D. F. Swaab, “Melatonin rhythmicity: effect of age and Alzheimer's disease,” Experimental Gerontology, vol. 38, no. 1-2, pp. 199–206, 2003. View at Publisher · View at Google Scholar · View at Scopus
  109. F. Magri, M. Locatelli, G. Balza et al., “Changes in endocrine circadian rhythms as markers of physiological and pathological brain aging,” Chronobiology International, vol. 14, no. 4, pp. 385–396, 1997. View at Google Scholar · View at Scopus
  110. S. M. McCurry, C. F. Reynolds, S. Ancoli-Israel, L. Teri, and M. V. Vitiello, “Treatment of sleep disturbance in Alzheimer's disease,” Sleep Medicine Reviews, vol. 4, no. 6, pp. 603–628, 2000. View at Publisher · View at Google Scholar · View at Scopus
  111. L. I. Brusco, M. Marquez, and D. P. Cardinali, “Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease,” Neuroendocrinology Letters, vol. 19, no. 3, pp. 111–115, 1998. View at Google Scholar · View at Scopus
  112. L. I. Brusco, M. Márquez, and D. P. Cardinali, “Monozygotic twins with alzheimer's disease treated with melatonin: case report,” Journal of Pineal Research, vol. 25, no. 4, pp. 260–263, 1998. View at Publisher · View at Google Scholar · View at Scopus
  113. K. Mishima, M. Okawa, S. Hozumi, and Y. Hishikawa, “Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons,” Chronobiology International, vol. 17, no. 3, pp. 419–432, 2000. View at Publisher · View at Google Scholar · View at Scopus
  114. R. Mahlberg, D. Kunz, I. Sutej, K. P. Kühl, and R. Hellweg, “Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy,” Journal of Clinical Psychopharmacology, vol. 24, no. 4, pp. 456–459, 2004. View at Google Scholar · View at Scopus
  115. D. P. Cardinali, L. I. Brusco, C. Liberczuk, and A. M. Furio, “The use of melatonin in Alzheimer's disease,” Neuroendocrinology Letters, vol. 23, no. 1, pp. 20–23, 2002. View at Google Scholar · View at Scopus
  116. I. Fainstein, A. J. Bonetto, L. I. Brusco, and D. P. Cardinali, “Effects of melatonin in elderly patients with sleep disturbance: a pilot study,” Current Therapeutic Research—Clinical and Experimental, vol. 58, no. 12, pp. 990–1000, 1997. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Cohen-Mansfield, D. Garfinkel, and S. Lipson, “Melatonin for treatment of sundowning in elderly persons with dementia—a preliminary study,” Archives of Gerontology and Geriatrics, vol. 31, no. 1, pp. 65–76, 2000. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Serfaty, S. Kennell-Webb, J. Warner, R. Blizard, and P. Raven, “Double blind randodmised placebo controlled trial of low dose melatonin for sleep disorders in dementia,” International Journal of Geriatric Psychiatry, vol. 17, no. 12, pp. 1120–1127, 2002. View at Publisher · View at Google Scholar
  119. K. Asayama, H. Yamadera, T. Ito, H. Suzuki, Y. Kudo, and S. Endo, “Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia,” Journal of Nippon Medical School, vol. 70, no. 4, pp. 334–341, 2003. View at Google Scholar · View at Scopus
  120. C. Singer, R. E. Tractenberg, J. Kaye et al., “A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease,” Sleep, vol. 26, no. 7, pp. 893–901, 2003. View at Google Scholar · View at Scopus
  121. R. Mahlberg and S. Walther, “Actigraphy in agitated patients with dementia: monitoring treatment outcomes,” Zeitschrift fur Gerontologie und Geriatrie, vol. 40, no. 3, pp. 178–184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. G. A. Dowling, R. L. Burr, E. J. W. van Someren et al., “Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease,” Journal of the American Geriatrics Society, vol. 56, no. 2, pp. 239–246, 2008. View at Publisher · View at Google Scholar
  123. K. N. Anderson, S. Jamieson, A. J. Graham, and J. M. Shneerson, “REM sleep behaviour disorder treated with melatonin in a patient with Alzheimer's disease,” Clinical Neurology and Neurosurgery, vol. 110, no. 5, pp. 492–495, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. P. R. Gehrman, D. J. Connor, J. L. Martin, T. Shochat, J. Corey-Bloom, and S. Ancoli-Israel, “Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with alzheimer disease,” American Journal of Geriatric Psychiatry, vol. 17, no. 2, pp. 166–169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. D. P. Cardinali, A. M. Furio, and L. I. Brusco, “Clinical aspects of melatonin intervention in Alzheimer's disease progression,” Current Neuropharmacology, vol. 8, no. 3, pp. 218–227, 2010. View at Google Scholar
  126. Y. H. Wu, J. N. Zhou, J. van Heerikhuize, R. Jockers, and D. F. Swaab, “Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease,” Neurobiology of Aging, vol. 28, no. 8, pp. 1239–1247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  127. Y. H. Wu, D. F. Fischer, A. Kalsbeek et al., “Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock",” The FASEB Journal, vol. 20, no. 11, pp. 1874–1876, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. Y. H. Wu and D. F. Swaab, “Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease,” Sleep Medicine, vol. 8, no. 6, pp. 623–636, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. J. Quinn, D. Kulhanek, J. Nowlin et al., “Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials,” Brain Research, vol. 1037, no. 1-2, pp. 209–213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Gauthier, B. Reisberg, M. Zaudig et al., “Mild cognitive impairment,” Lancet, vol. 367, no. 9518, pp. 1262–1270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. G. Jean-Louis, H. von Gizycki, and F. Zizi, “Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment,” Journal of Pineal Research, vol. 25, no. 3, pp. 177–183, 1998. View at Publisher · View at Google Scholar · View at Scopus
  132. J. S. Peck, D. B. LeGoff, I. Ahmed, and D. Goebert, “Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study,” American Journal of Geriatric Psychiatry, vol. 12, no. 4, pp. 432–436, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. A. M. Furio, L. I. Brusco, and D. P. Cardinali, “Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study,” Journal of Pineal Research, vol. 43, no. 4, pp. 404–409, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. A. G. Wade, I. Ford, G. Crawford et al., “Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes,” Current Medical Research and Opinion, vol. 23, no. 10, pp. 2597–2605, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. C. Garzón, J. M. Guerrero, O. Aramburu, and T. Guzmán, “Effecf of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study,” Aging—Clinical and Experimental Research, vol. 21, no. 1, pp. 38–42, 2009. View at Google Scholar
  136. M. Miyamoto, “Pharmacology of ramelteon, a selective MT/MT receptor agonist: a novel therapeutic drug for sleep disorders,” CNS Neuroscience and Therapeutics, vol. 15, no. 1, pp. 32–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  137. E. J. Sanchez-Barcelo, C. M. Martinez-Campa, M. D. Mediavilla et al., “Melatonin and melatoninergic drugs as therapeutic agents: ramelteon and agomelatine, the two most promising melatonin receptor agonists,” Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, vol. 1, pp. 142–151, 2007. View at Google Scholar
  138. K. Kato, K. Hirai, K. Nishiyama et al., “Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist,” Neuropharmacology, vol. 48, no. 2, pp. 301–310, 2005. View at Publisher · View at Google Scholar · View at Scopus
  139. N. Zisapel, “Sleep and sleep disturbances: biological basis and clinical implications,” Cellular and Molecular Life Sciences, vol. 64, no. 10, pp. 1174–1186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. C. Cajochen, “TAK-375 Takeda,” Current Opinion in Investigational Drugs, vol. 6, no. 1, pp. 114–121, 2005. View at Google Scholar · View at Scopus
  141. S. Stevenson, S. Bryson, D. Amayke et al., “Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects,” Clinical Pharmacology and Therapeutics, vol. 75, p. P22, 2004. View at Google Scholar
  142. D. J. Greenblatt, J. S. Harmatz, and A. Karim, “Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2,” Journal of Clinical Pharmacology, vol. 47, no. 4, pp. 485–496, 2007. View at Publisher · View at Google Scholar · View at Scopus
  143. T. Roth, D. Seiden, S. Sainati, S. Wang-Weigand, J. Zhang, and P. Zee, “Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia,” Sleep Medicine, vol. 7, no. 4, pp. 312–318, 2006. View at Publisher · View at Google Scholar · View at Scopus
  144. T. Roth, D. Seiden, S. Wang-Weigand, and J. Zhang, “A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia,” Current Medical Research and Opinion, vol. 23, no. 5, pp. 1005–1014, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. G. Zammit, M. Erman, S. Wang-Weigand, S. Sainati, J. Zhang, and T. Roth, “Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia,” Journal of Clinical Sleep Medicine, vol. 3, no. 5, pp. 495–504, 2007. View at Google Scholar · View at Scopus
  146. G. Zammit, H. Schwartz, T. Roth, S. Wang-Weigand, S. Sainati, and J. Zhang, “The effects of ramelteon in a first-night model of transient insomnia,” Sleep Medicine, vol. 10, no. 1, pp. 55–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  147. G. Mayer, S. Wang-Weigand, B. Roth-Schechter, R. Lehmann, C. Staner, and M. Partinen, “Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia,” Sleep, vol. 32, no. 3, pp. 351–360, 2009. View at Google Scholar · View at Scopus
  148. M. Kryger, S. Wang-Weigand, and T. Roth, “Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea,” Sleep and Breathing, vol. 11, no. 3, pp. 159–164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  149. E. C. Lauterbach, J. Victoroff, K. L. Coburn, S. D. Shillcutt, S. M. Doonan, and M. F. Mendez, “Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 22, no. 1, pp. 8–18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. A. M. Mathes, D. Kubulus, L. Waibel et al., “Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat,” Critical Care Medicine, vol. 36, no. 10, pp. 2863–2870, 2008. View at Publisher · View at Google Scholar
  151. D. Tan, R. J. Reiter, L. Chen, B. Poeggeler, L. C. Manchester, and L. R. Barlow-Walden, “Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole,” Carcinogenesis, vol. 15, no. 2, pp. 215–218, 1994. View at Google Scholar · View at Scopus
  152. R. J. Reiter, D. X. Tan, J. C. Mayo, R. M. Sainz, J. Leon, and Z. Czarnocki, “Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans,” Acta Biochimica Polonica, vol. 50, no. 4, pp. 1129–1146, 2003. View at Google Scholar · View at Scopus
  153. R. Hardeland and S. R. Pandi-Perumal, “Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug,” Nutrition and Metabolism, vol. 2, article 22, 2005. View at Publisher · View at Google Scholar · View at Scopus
  154. S. R. Pandi-Perumal, V. Srinivasan, G. J. M. Maestroni, D. P. Cardinali, B. Poeggeler, and R. Hardeland, “Melatonin: nature's most versatile biological signal?” FEBS Journal, vol. 273, no. 13, pp. 2813–2838, 2006. View at Publisher · View at Google Scholar · View at Scopus
  155. R. Hardeland and B. Poeggeler, “Melatonin beyond its classical functions,” Open Physiology Jounal, vol. 1, pp. 1–23, 2008. View at Google Scholar
  156. P. Brunner, N. Sözer-Topcular, R. Jockers et al., “Pineal and cortical melatonin receptors MT1 and MT1 are decreased in Alzheimer's disease,” European Journal of Histochemistry, vol. 50, no. 4, pp. 311–316, 2006. View at Google Scholar · View at Scopus
  157. E. Savaskan, M. A. Ayoub, R. Ravid et al., “Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease,” Journal of Pineal Research, vol. 38, no. 1, pp. 10–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  158. E. Savaskan, R. Jockers, M. Ayoub et al., “The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer's disease,” Current Alzheimer Research, vol. 4, no. 1, pp. 47–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  159. E. Savaskan, G. Olivieri, L. Brydon et al., “Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer's disease,” Neuroscience Letters, vol. 308, no. 1, pp. 9–12, 2001. View at Publisher · View at Google Scholar · View at Scopus
  160. L. P. Niles, K. J. Armstrong, L. M. Rincón Castro et al., “Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers,” BMC Neuroscience, vol. 5, article 41, 2004. View at Publisher · View at Google Scholar · View at Scopus
  161. X. Kong, X. Li, Z. Cai et al., “Melatonin regulates the viability and differentiation of rat midbrain neural stem cells,” Cellular and Molecular Neurobiology, vol. 28, no. 4, pp. 569–579, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. M. Imbesi, T. Uz, S. Dzitoyeva, and H. Manev, “Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells,” Neuroscience Letters, vol. 439, no. 1, pp. 34–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  163. R. E. Rosenstein, S. R. Pandi-Perumal, V. Srinivasan, D. W. Spence, G. M. Brown, and D. P. Cardinali, “Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis,” Journal of Pineal Research, vol. 49, no. 1, pp. 1–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  164. F. Benedetti, A. Serretti, C. Colombo, C. Lorenzi, V. Tubazio, and E. Smeraldi, “A glycogen synthase kinase 3-β promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression,” Neuroscience Letters, vol. 368, no. 2, pp. 123–126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  165. A. Sehgal, W. Joiner, A. Crocker et al., “Molecular analysis of sleep: wake cycles in Drosophila,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 72, pp. 557–564, 2007. View at Publisher · View at Google Scholar · View at Scopus
  166. L. Lavie and P. Lavie, “Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link,” European Respiratory Journal, vol. 33, no. 6, pp. 1467–1484, 2009. View at Publisher · View at Google Scholar · View at Scopus
  167. C. Cirelli and G. Tononi, “Uncoupling proteins and sleep deprivation,” Archives Italiennes de Biologie, vol. 142, no. 4, pp. 541–549, 2004. View at Google Scholar · View at Scopus
  168. C. Cirelli, U. Faraguna, and G. Tononi, “Changes in brain gene expression after long-term sleep deprivation,” Journal of Neurochemistry, vol. 98, no. 5, pp. 1632–1645, 2006. View at Publisher · View at Google Scholar · View at Scopus